The Journal of Allergy and Clinical Immunology
Volume 126, Issue 1 , Pages 52-58.e5 , July 2010

Serum vitamin D levels and severe asthma exacerbations in the Childhood Asthma Management Program study

  • John M. Brehm, MD, MPH

      Affiliations

    • Channing Laboratory, Department of Medicine, Brigham and Women's Hospital, Boston, Mass
    • Division of Pulmonary/Critical Care Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, Mass
    • Department of Medicine, Harvard Medical School, Boston, Mass
    • ,
  • Brooke Schuemann, BS

      Affiliations

    • Channing Laboratory, Department of Medicine, Brigham and Women's Hospital, Boston, Mass
    • ,
  • Anne L. Fuhlbrigge, MD

      Affiliations

    • Channing Laboratory, Department of Medicine, Brigham and Women's Hospital, Boston, Mass
    • Division of Pulmonary/Critical Care Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, Mass
    • ,
  • Bruce W. Hollis, PhD

      Affiliations

    • Darby Children's Research Institute, Medical University of South Carolina, Charleston, SC
    • ,
  • Robert C. Strunk, MD

      Affiliations

    • Division of Allergy and Pulmonary Medicine, Department of Pediatrics, Washington University School of Medicine and St Louis Children's Hospital, St Louis, Mo
    • ,
  • Robert S. Zeiger, MD, PhD

      Affiliations

    • Department of Allergy, Kaiser Permanente Medical Center, San Diego, Calif
    • ,
  • Scott T. Weiss, MD, MS

      Affiliations

    • Channing Laboratory, Department of Medicine, Brigham and Women's Hospital, Boston, Mass
    • Division of Pulmonary/Critical Care Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, Mass
    • Center for Genomic Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, Mass
    • Department of Medicine, Harvard Medical School, Boston, Mass
    • These authors contributed equally to this work.
    • ,
  • Augusto A. Litonjua, MD, MPH

      Affiliations

    • Channing Laboratory, Department of Medicine, Brigham and Women's Hospital, Boston, Mass
    • Division of Pulmonary/Critical Care Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, Mass
    • Department of Medicine, Harvard Medical School, Boston, Mass
    • Corresponding Author InformationReprint requests: Augusto A. Litonjua, MD, MPH, Channing Laboratory, 181 Longwood Ave, Boston, MA 02115.
    • These authors contributed equally to this work.
    • ,
  • Childhood Asthma Management Program Research Group

      Affiliations

    • Members of the Childhood Asthma Management Program Research Group are detailed in this article's Online Repository at www.jacionline.org.

Received 22 October 2009 ,Revised 27 March 2010 ,Accepted 30 March 2010.

  • Image Result

    Vitamin D levels and distributions by study center (A), season (B), and race (C).

    Vitamin D levels and distributions by study center (A), season (B), and race (C).

  • Image Result

    Sensitivity analysis of risk of hospitalization or ED visit by vitamin D level. The probabilities of severe exacerbations were plotted for the range of vitamin D levels in the study, and a smoothing f

    Sensitivity analysis of risk of hospitalization or ED visit by vitamin D level. The probabilities of severe exacerbations were plotted for the range of vitamin D levels in the study, and a smoothing function was used to draw a line through the values. Vertical lines represent quartiles of vitamin D levels. The risk of hospitalization starts to decrease around a vitamin D level of 30 ng/mL.

  • Image Result
    Distribution of vitamin D levels at randomization in all subjects.

    Distribution of vitamin D levels at randomization in all subjects.

 We acknowledge the Childhood Asthma Management Program (CAMP) investigators and research team, supported by the National Heart, Lung, and Blood Institute, for collection of CAMP Genetics Ancillary Study data. All work on data collected from the CAMP Genetics Ancillary Study was conducted at the Channing Laboratory of the Brigham and Women's Hospital under appropriate CAMP policies and human subject's protections. The CAMP Genetics Ancillary Study is supported by U01 HL075419, U01 HL65899, P01 HL083069, R01 HL086601, and T32 HL07427 from the National Heart, Lung, and Blood Institute(NHLBI)/National Institutes of Health. We also acknowledge the Asthma Clinical Research Network (ACRN) investigators and research teams supported by U01 HL51510, U01 HL51834, U01 HL51831, U01 HL51845, U01 HL 51843, M01 RR00079, and M01 RR03186 from the NHLBI. This work was also supported by National Institutes of Health grant R21HL089842.

 Disclosure of potential conflict of interest: A. L. Fuhlbrigge is on an advisory board for and has given talks for Merck and has received continuing medical education from Advanced Health Media, funded through GlaxoSmithKline. B. W. Hollis has consulted for DiaSorin and has received research support from the National Institutes of Health. R. S. Zeiger has consulted for AstraZeneca, Aerocrine, Genentech, Novartis, Merck, Schering-Plough, and MedImmune and has received indirect research support from Aerocrine, Genentech, GlaxoSmithKline, Merck, AstraZeneca, and TEVA Pharmaceuticals. A. A. Litonjua has received research support from the National Institutes of Health. The rest of the authors have declared that they have no conflict of interest.

PII: S0091-6749(10)00657-3

doi: 10.1016/j.jaci.2010.03.043

The Journal of Allergy and Clinical Immunology
Volume 126, Issue 1 , Pages 52-58.e5 , July 2010

Article Tools

* Image Usage & Resolution